1
|
Barrón-Barrón F, Guzmán-De Alba E, Alatorre-Alexander J, Aldaco-Sarvider F, Bautista-Aragón Y, Blake-Cerda M, Blanco-Vázquez YC, Campos-Gómez S, Corona-Cruz JF, Iñiguez-García MA, Lozano-Ruiz FJ, Maldonado-Magos F, de la Mata-Moya D, Martínez-Barrera LM, Ramos-Prudencio R, Rodríguez-Cid J, Rivera-Rivera S, Trejo-Rosales RR, Aguilar-Ortíz MR, Astudillo-de la Vega H, Barajas-Figueroa LJ, Barroso-Quiroga N, Blanco-Salazar A, Castillo-Ortega G, Domínguez-Parra LM, Enriquez-Aceves MI, Fernández-Orozco A, Figueroa-Morales MA, Green-Schneewiss L, González-Garay JA, González Ramírez-Benfield R, Guadarrama-Orozco A, Guerrero-Ixtlahuac J, Hernández-Barajas D, Hernández-Montes de Oca R, Kelly-García J, Lázaro-León M, Silva-Bravo F, Tellez-Becerra JL, Macedo-Pérez EO, Maza-Ramos G, Mayorga-Butrón JL, Montaño-Velázquez BB, Murillo-Medina K, Narváez-Fernández S, Ochoa-Carrillo FJ, Olivares-Beltrán G, Olivares-Torres C, Ponce de León-Castillo M, Ponce-Viveros MA, Rubio-Gutiérrez JE, Sáenz-Frías JA, Silva-Vivas JA, Santillán-Doherty P, Soto-Ávila JJ, Toledo-Buenrostro V, Vargas-Abrego B, Velasco-Hidalgo L, Zapata-Tarres MM, Quintero-Beuló G, Arrieta O. National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. Salud Publica Mex 2020; 61:359-414. [PMID: 31276353 DOI: 10.21149/9916] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 01/28/2019] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVE Lung cancer is one the leading causes of mortality worldwide. Symptomatic manifestations of the disease generally occur in the advanced-stage setting, and therefore an important number of patients have advanced or metastatic disease by the time they are diagnosed. This situation contributes to a poor prognosis in the treatment of lung cancer. Evidencebased clinical recommendations are of great value to support decision-making for daily practice, and thus improving health care quality and patient outcomes. MATERIALS AND METHODS This document was an initiative of the Mexican Society of Oncology (SMEO) in collaboration with Mexican Center of Clinical Excellence (Cenetec) according to Interna- tional Standards. Such standards included those described by the IOM, NICE, SIGN and GI-N. An interdisciplinary Guideline Development Group (GDG) was put together which included medical oncologists, surgical oncologistsc, radiation therapists, and methodologists with expertise in critical appraisal, sys- tematic reviews and clinical practice guidelines development. RESULTS 62 clinical questions were agreed among members of the GDG. With the evidence identified from systematic reviews, the GDG developed clinical recommendations using a Modified Delphi Panel technique. Patients' representatives validated them. CONCLUSIONS These Clinical Practice Guideline aims to support the shared decision-making process for patients with different stages of non-small cell lung cancer. Our goal is to improve health-care quality on these patients.
Collapse
Affiliation(s)
| | | | | | - Fernando Aldaco-Sarvider
- Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México
| | - Yolanda Bautista-Aragón
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | | | | | - Saúl Campos-Gómez
- Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios. Estado de México, México
| | | | | | | | | | | | | | - Rubí Ramos-Prudencio
- Instituto Nacional de Ciencias Médicas y de la Nutrición Dr. Salvador Zubirán, SSA. Ciudad de México, México
| | | | - Samuel Rivera-Rivera
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | - Raúl Rogelio Trejo-Rosales
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | - Marco Rodrigo Aguilar-Ortíz
- Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios. Estado de México, México.,Steering Comitee, Guidelines International Network North America. New York, USA
| | - Horacio Astudillo-de la Vega
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | | | | | - Andrés Blanco-Salazar
- Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios. Estado de México, México
| | | | | | | | - Armando Fernández-Orozco
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | | | | | | | | | - Alberto Guadarrama-Orozco
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | | | | | | | | | - Miguel Lázaro-León
- Hospital General de México Dr. Eduardo Liceaga. Ciudad de México, México
| | | | | | | | - Gibert Maza-Ramos
- Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios. Estado de México, México.,Steering Comitee, Guidelines International Network North America. New York, USA
| | - José Luis Mayorga-Butrón
- Programa de Maestría y Doctorado en Ciencias Médicas, Unidad de Posgrado, Facultad de Medicina, UNAM. Ciudad de México, México.,Instituto Nacional de Pediatría, Ciudad de México, México
| | | | - Karina Murillo-Medina
- Hospital Regional General Zaragoza, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, México
| | | | | | | | | | | | - Mario Alberto Ponce-Viveros
- Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México
| | | | | | | | - Patricio Santillán-Doherty
- Instituto Nacional de Ciencias Médicas y de la Nutrición Dr. Salvador Zubirán, SSA. Ciudad de México, México
| | | | | | | | | | | | | | - Oscar Arrieta
- Instituto Nacional de Cancerología. Ciudad de México, México
| |
Collapse
|
2
|
Arrieta O, Guzmán-de Alba E, Alba-López LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, Allende-Pérez SR, Alvarado-Aguilar S, Araujo-Navarrete ME, Argote-Greene LM, Aquino-Mendoza CA, Astorga-Ramos AM, Austudillo-de la Vega H, Avilés-Salas A, Barajas-Figueroa LJ, Barroso-Quiroga N, Blake-Cerda M, Cabrera-Galeana PA, Calderillo-Ruíz G, Campos-Parra AD, Cano-Valdez AM, Capdeville-García D, Castillo-Ortega G, Casillas-Suárez C, Castillo-González P, Corona-Cruz JF, Correa-Acevedo ME, Cortez-Ramírez SS, de la Cruz-Vargas JA, de la Garza-Salazar JG, de la Mata-Moya MD, Domínguez-Flores ME, Domínguez-Malagón HR, Domínguez-Parra LM, Domínguez-Peregrina A, Durán-Alcocer J, Enríquez-Aceves MI, Elizondo-Ríos A, Escobedo-Sánchez MD, de Villafranca PEM, Flores-Cantisani A, Flores-Gutiérrez JP, Franco-Marina F, Franco-González EE, Franco-Topete RA, Fuentes-de la Peña H, Galicia-Amor S, Gallardo-Rincón D, Gamboa-Domínguez A, García-Andreu J, García-Cuéllar CM, García-Sancho-Figueroa MC, García-Torrentera R, Gerson-Cwilich R, Gómez-González A, Green-Schneeweiss L, Guillén-Núñez MDR, Gutiérrez-Velázquez H, Ibarra-Pérez C, Jiménez-Fuentes E, Juárez-Sánchez P, Juárez-Ramiro A, Kelly-García J, Kuri-Exsome R, Lázaro-León JM, León-Rodríguez E, Llanos-Osuna S, Llanos-Osuna S, Loyola-García U, López-González JS, López y de Antuñano FJ, Loustaunau-Andrade MA, Macedo-Pérez EO, Machado-Villarroel L, Magallanes-Maciel M, Martínez-Barrera L, Martínez-Cedillo J, Martínez-Martínez G, Medina-Esparza A, Meneses-García A, Mohar-Betancourt A, Morales Blanhir J, Morales-Gómez J, Motola-Kuba D, Nájera-Cruz MP, Núñez-Valencia CDC, Ocampo-Ocampo MA, Ochoa-Vázquez MD, Olivares-Torres CA, Palomar-Lever A, Patiño-Zarco M, Pérez-Padilla R, Peña-Alonso YR, Pérez-Romo AR, Aquilino Pérez M, Pinaya-Ruíz PM, Pointevin-Chacón MA, Poot-Braga JJ, Posadas-Valay R, Ramirez-Márquez M, Reyes-Martínez I, Robledo-Pascual J, Rodríguez-Cid J, Rojas-Marín CE, Romero-Bielma E, Rubio-Gutiérrez JE, Sáenz-Frías JA, Salazar-Lezama MA, Sánchez-Lara K, Sansores Martínez R, Santillán-Doherty P, Alejandro-Silva J, Téllez-Becerra JL, Toledo-Buenrostro V, Torre-Bouscoulet L, Torecillas-Torres L, Torres M, Tovar-Guzmán V, Turcott-Chaparro JG, Vázquez-Cortés JJ, Vázquez-Manríquez ME, Vilches-Cisneros N, Villegas-Elizondo JF, Zamboni MM, Zamora-Moreno J, Zinser-Sierra JW. [National consensus of diagnosis and treatment of non-small cell lung cancer]. Rev Invest Clin 2013; 65 Suppl 1:S5-S84. [PMID: 24459776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Mexican specialists in oncology, oncologic surgery, thoracic surgery, pneumology, pathology, molecular biology, anesthesiology, algology, psychology, nutrition, and rehabilitation (all of them experts in lung cancer treatment) in order to develop the National Consensus on Lung Cancer. The consensus has been developed as an answer to the need of updated Mexican guidelines for the optimal treatment of the disease, as well as to the requirements that such guidelines be established by multidisciplinary panel, depicting the current attention given to cancer lung cases in Mexico. Thus, this paper analyses the epidemiological review, screening, diagnosis, staging, pathology, translational medicine, and the suitable therapies for early, locally advanced, and metastatic disease in the first, second, and third lines of management, as well as rehabilitation and palliative measures.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Mauro M Zamboni
- Asociación Latinoamericana de Tórax, Instituto Nacional de Cáncer, Brasil
| | | | | |
Collapse
|
3
|
Barajas MA, Ramírez-Guzman MG, Rodríguez-Vázquez C, Toledo-Buenrostro V, Cuevas-Solórzano A, Rodríguez-Hernández G. Gamma knife surgery for hypothalamic hamartomas accompanied by medically intractable epilepsy and precocious puberty: experience in Mexico. J Neurosurg 2005; 102 Suppl:53-5. [PMID: 15662781 DOI: 10.3171/jns.2005.102.s_supplement.0053] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT Hypothalamic hamartoma is a nonneoplastic malformative mass of neurons and glia in the region of the hypothalamus. Because of its location, open surgery is associated with high morbidity and mortality rates. Gamma knife surgery (GKS) may be an efficient and safe treatment approach, which produces little morbidity. The authors describe the results of GKS in three patients with hypothalamic hamartomas. METHODS All patients were male, aged 3, 12, and 15 years. The lesions were classified according to the Valdueza scale: one was Type IIb and two were Type IIa. The patients presented with gelastic seizures (15-20 per day), generalized epilepsy, behavioral abnormalities, and alterations of the sleep cycle. Precocious puberty was present in one patient. The Type IIb tumor had a volume of 1.8 cm3, and the Type IIa tumors were 597 mm3 and 530.1 mm3. The lesions received 12.5 Gy, 14 Gy, and 15 Gy, respectively, to the 50% isodose line. The patients were followed for 30 to 50 months. After 3 months, all patients showed improvement of their sleep, behavior, and epilepsy. At the present time, these patients are receiving low-dose antiepileptic agents and have achieved adequate social development and school integration. CONCLUSIONS Gamma knife surgery appears to be a good, safe, and effective option for the treatment of selected hypothalamic hamartomas. No morbidity or mortality was associated with these three cases.
Collapse
Affiliation(s)
- Marco A Barajas
- Neurosciences Division, Gamma Knife Unit, Neuroradiology Department, Hospital San Javier, Guadalajara, Jalisco, Mexico
| | | | | | | | | | | |
Collapse
|
4
|
Barajas MA, G. Ramírez-Guzmán M, Rodríguez-Vázquez C, Toledo-Buenrostro V, Cuevas-Solórzano A, Rodríguez-Hernández G. Gamma knife surgery for hypothalamic hamartomas accompanied by medically intractable epilepsy and precocious puberty: experience in Mexico. J Neurosurg 2005. [DOI: 10.3171/sup.2005.102.s_supplement.0053] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object. Hypothalamic hamartoma is a nonneoplastic malformative mass of neurons and glia in the region of the hypothalamus. Because of its location, open surgery is associated with high morbidity and mortality rates. Gamma knife surgery (GKS) may be an efficient and safe treatment approach, which produces little morbidity. The authors describe the results of GKS in three patients with hypothalamic hamartomas.
Methods. All patients were male, aged 3, 12, and 15 years. The lesions were classified according to the Valdueza scale: one was Type IIb and two were Type IIa. The patients presented with gelastic seizures (15–20 per day), generalized epilepsy, behavioral abnormalities, and alterations of the sleep cycle. Precocious puberty was present in one patient. The Type IIb tumor had a volume of 1.8 cm3, and the Type IIa tumors were 597 mm3 and 530.1 mm3. The lesions received 12.5 Gy, 14 Gy, and 15 Gy, respectively, to the 50% isodose line. The patients were followed for 30 to 50 months. After 3 months, all patients showed improvement of their sleep, behavior, and epilepsy. At the present time, these patients are receiving low-dose antiepileptic agents and have achieved adequate social development and school integration.
Conclusions. Gamma knife surgery appears to be a good, safe, and effective option for the treatment of selected hypothalamic hamartomas. No morbidity or mortality was associated with these three cases.
Collapse
|
5
|
Barajas MA, Ramírez-Guzmán G, Rodríguez-Vázquez C, Toledo-Buenrostro V, Velásquez-Santana H, Robles RDV, Cuevas-Solórzano A, Rodríguez-Hernández G. Multimodal management of craniopharyngiomas: neuroendoscopy, microsurgery, and radiosurgery. J Neurosurg 2002. [DOI: 10.3171/jns.2002.97.supplement_5.0607] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object. The goal of this study was to examine the role of gamma knife radiosurgery (GKS) and adjuvant neuroendoscopic procedures by assessing the outcome in 10 patients with craniopharyngiomas who were treated between 1998 and 2001.
Methods. In 10 consecutive patients (six males and four females, mean age 12 years [range 7–32 years]), there were nine mixed and one solid craniopharyngioma. In the last three cases, neuroendoscopic procedures were conducted. Two cases required insertion of an Ommaya reservoir. In another case partial removal of the cyst wall was performed using an endoscope to create a communication with the cerebrospinal pathways and thereby preclude the need for shunt insertion.
Conclusions. Multimodal management of craniopharyngiomas seems to provide a better rate of survival and greater long-term disease control. It is suggested that GKS combined with adjuvant neuroendoscopy should be used as an alternative in treating recurrent or residual craniopharyngiomas if additional microsurgical removal cannot guarantee a cure.
Collapse
|